View
224
Download
5
Category
Preview:
Citation preview
1
Creating Value From Innovation
presented by
Baldwins Intellectual Propertyand PricewaterhouseCoopers
2
Justin LiddellPricewaterhouseCoopersPartner, Corporate FinanceValuation and Strategy
DDI: +64 9 355 8330Email: justin.g.liddell@nz.pwc.com
• Justin has provided valuation advice and opinionsto numerous leading New Zealand andinternational corporates in his 13 years ofexperience in New Zealand and London.
• Justin’s valuation experience spans numerousindustries with particular expertise in the valuationof intangible assets, whether for financialreporting or other purposes.
Your ExpertsWes JonesBaldwins Intellectual PropertyPartner
DDI: +64 9 359 7747Email: wes.jones@baldwins.com
• Wes works primarily in the areas of patents,particularly in the electronics field, but alsoadvises on copyright and design protection. Hespecialises in drafting patent specifications,providing validity and infringement advice,preparing license and other technology transferagreements and advising on intellectual propertyportfolio management.
Rosemary WallisBaldwins Intellectual PropertyPartner
DDI: +64 9 359 7733Email: rosemary.wallis@baldwins.com
• Rosemary works in the area of dispute resolutionacross all areas of intellectual property, and inthe licensing and franchising fields. This includeswork on patent, copyright, trade mark and designdisputes and litigation, providing advice on thecommercialisation of intellectual property andpreparing licensing and technology transferagreements.
Eric LucasPricewaterhouseCoopersPartner, Corporate FinanceValuation and Strategy
DDI: +64 9 355 8647Email: eric.lucas@nz.pwc.com
• Eric is a Corporate Finance Partner withPricewaterhouseCoopers and responsible for theFirm’s Dispute Analysis Practice in NewZealand.
• He has provided complex valuation advice to awide variety of clients, from companies such asFonterra Co-operative Group Limited to smallbusinesses, with particular emphasis onconsumer and industrial product companies.
Mike MorganPricewaterhouseCoopersPartner, TaxMergers & Acquisitions
DDI: +64 9 355 8708Email: mike.j.morgan@nz.pwc.com
• Mike is a Partner in our mergers and acquisitionstax group, specialising in tax due diligence andstructuring for corporate, SME and private equityclients.
• Mike’s experience includes advising on taxeffective structures for intellectual property,particularly for clients in the ICT and biotechindustries.
Tim WhitePricewaterhouseCoopersDirectorPrivate Client Services
DDI: +64 9 355 8216Email: tim.h.white@nz.pwc.com
• Tim provides strategic advice to private companiesincluding strategic and business planning, businessreviews, mergers and acquisitions, capital raising,sustainable cost management, and financialmodelling.
• He is responsible for driving the firm’s EmergingBusiness strategy in Auckland and has a particularinterest in high growth business.
3
Contents
• Innovation vs Commercialisation• IP Protection• Tax Optimisation• Commercialisation
4
Innovation vs Commercialisation – Tim White
5
Innovation vs Commercialisation
Difference Between Innovation and Commercialisation
• Markets rewards commercialisation – not innovation
Innovation– In 1973 the Palo Alto PC (PAPC) became operational and developed:
• mouse• GUI• PAPC also developed Ethernet and laser printer
Commercialisation– Apple successfully commercialised GUI– 3Com successfully commercialised Ethernet– Betamax vs. VHS
6
Innovation vs Commercialisation
Commercialising/Monetising IP
• The basic building blocks of commercialisation
Goo
dId
ea
Execution
Externalities
• Market-driven or an innovation lookingfor an application?
• You need to have:– An executable plan– Awareness of, and strategies around
those things you can’t directly influence
7
Innovation vs Commercialisation
Challenges: From the Creation of an Idea – toCommercialisation – to Exit
• The Technology Adoption life Cycle
Source: Chasm Group
8
Innovation vs Commercialisation
Access to CapitalAt least a year
of cashminimum
Batten downthe hatches
Raise yourfunding as soon
as possible
Pursue M&Aopportunities
Be realistic onvaluations
The VC community will startexercising their leverage
9
IP Protection – Wes Jones
10
Why is IP Important?
• Provides the legal framework for recognising / protecting your innovation
• Knowledge economy
• Employee Mobility and ease of information transfer
• Greater awareness in capital markets
11
How and When to Protect Your IP
• Patents, Registered Designs, Trade Marks, Copyright and ConfidentialInformation
• Patent System – first in, best dressed
• Importance of Branding
• Who owns that IP?
12
IP Management
• Maintaining an awareness of the “IP Landscape” in which you operate
• Internal recognition and capture of IP
• Alignment of IP Strategy and processes with corporate strategy andprocesses
13
IP Capture
• Build into R&D processes – or at least create awareness of IP
• Use of Invention/Innovation Disclosure
• Importance of confidentiality
• Written employment contracts
• IP database
14
• Pre- patent filing and post-filing
• Physical measures
• Agreements with employees and external entities
• Careful consideration of patent filing vs maintaining confidentiality
Confidentiality
15
IP Landscape – The Process
• Identify technology competitors
• Identify prospective licensees
• Develop searching strategy
• Select the data
• Process the data (e.g. visual map)
• Use it for strategy, planning and minimising infringement risk
16
IP Landscape
17
IP Landscape
18
• Offer ongoing protection
• Should be part of the IP landscape exercise
• Be aware of territorial issues
Building and Protecting Brands
19
Tax Optimisation – Mike Morgan
20
Tax Optimisation
Disposal of IP
What is taxable?
– Sale of patents, patent applications (complete spec)
– Licence fees, royalties, payments for right to use
– Sale of any IP developed or acquired for purpose of disposal
What is not taxable?
– Sale of know-how, brands, trademarks, copyright not developed or acquired forpurpose of disposal
– Sale of shares to an IP holding company (conditions apply)
• Proceeds from sale of patents rights can be spread over three years
21
Tax Optimisation
Costs of Developing IP
What is deductible?
– Costs of underlying research if expensed for accounting
– Cost of acquiring / applying for patent (depreciable over legal life)
– Payments for right to use other IP
What is not deductible?
– Cost of acquiring brands, trademarks, know-how, copyrights
• Special rules for timing of some tax relief (deferral by election)
22
Tax Optimisation
Structuring Considerations
• Ownership Structure
– Individual vs. Company vs. Trust
• R&D Tax Credit
– Must control results of R&D
• GST
– Recovery of GST on costs/GST on sale or licence
Early Consideration is Key!!
23
Tax Optimisation
Keeping the Tax Man at Bay
• IRD Attitude
– Sensitive to IP transactions• Especially sale and licence back
– Will review and challenge valuations
– Split between patent rights and underlying invention
– Alienation of know-how possible?
– Keep tax compliance up-to-date
24
Commercialisation – Eric Lucas & Rosemary Wallis
25
Commercialisation – THE PROBLEM
• Your idea is only the start…..
• How developed is it really?
• Who knows about it?
• Who cares about it?
• Who would like it gone?
• What is its real potential?
• What help do you need to commercialise?
26
Commercialisation – THE PROBLEM
• No Distribution
• No Value
27
How developed is it?
• Working model?
• Prototype?
• Made in small quantities
• Made in commercial quantities
• Regulatory requirements?
28
What is its real potential?
• Market?
• Alternative solutions?
• How copiable?
• Competitor response?
• How long have you got?– e.g. Value
October 2002 $20m(0 – 44)October 2005 $11m(0 – 46)June 2008 $0
29
What help do you need to commercialise?
• Product development capability?– Regulatory?
• Production capability– Physical– Organisational
• Sales / Marketing capability
• Distribution capability:
• Typically comes down to:– Money and– Skills
• One size does not fit all
30
There are many solutions, but each has its challenges
• Capital injection
• Provision of skills
• Joint venture
• Licensing arrangements
Challenges: - Value of innovation
- Value of contribution / relative contributions
- What royalty rate?
• Sources of Capital
Capital may be expensiveCapital may be expensive
31
Value your innovation
• The innovator:– Optimistic
– Believes in the idea (blinkered?)
– May not understand the value of distribution
– May over value
• Costs to replicate often bring us to earth
• Usually DCF BUT!
– Start up cash flows hugely uncertain – wide range of outcomes
– Discount rates horrifying……
32
Seed Capital – Proof of concept
Start-up – Initial commercialisation and sale
First stage – Funds to initiate full-scale manufacturing/sale
Second stage – growth financefor operational entity, not yetprofitableThird stage – major expansion
Discount Rate Continuum
% 10 50 90
Second Stage
Third Stage
LBO
First Stage
Start Up
Seed Capital
33
Uncertainty lends itself to risk sharing
• Licensing fee spectrum
• Share risks and rewards
– Theoretically value implications should be the same
– Effect of royalty arrangements often not immediately obvious
– Easier to live with over time……
BUTBUT Hard to get the royalty rates ‘right’
• Rule of thumb for licensing
One off fee Fixed and variable fees Royalty per unit/profit share
34
Indicative Royalty Rates
Industry Range(%)
Average(%)
Industry Range(%)
Average(%)
Apparel 0-10 4.0 Drugs 0-10 6.8
Automotive/parts 0-10 1.9 Electronics 0-20 6.6
Biotechnology 0-20 7.0 Entertainment 0-25 15.5
Communications 0-25 8.2 Food 0-15 5.5
Computers 0-15 10.8 Hospitality/Leisure 0-10 4.4
Computer software 0-30+ 12.0 Industrial Products 0-30+ 6.4
Consumer Products 0-15 4.3 Medical/Medical Products 0-30+ 8.3
Copyrights & Trademarks 5-15 10.6 Services 0-15 5.8
Distribution 0-10 5.2 Pharmaceutical – Pre clinical 0.3-25 4.3
Toys & Games 5-25 13.1 Pharmaceutical – Launched 5-28 11.6
35
Commercialisation – Closing the Deal
• Deal sheet – check before, during and after negotiation
• Know your BATNA
• Work out their objectives
• Don’t get too excited and give it all away for too little
• Time out to talk
• Balance the negotiating team
• Do you like them and do they fit your culture
36
• Not a “standard agreement”
• Document your own deal and how it works
• Assume it will go wrong and protect yourself
• Don’t give away too much
• Fair deals tend to last
Commercialisation – Agreements That Work
37
Commercialisation – Of What and Where?
• All fields of use or just one
• Designated products with options for more
• Worldwide – can they deliver
• Where’s the best chance of success
• Who pays for more/ongoing IP protection
• Early licensing – excite interest
• Don’t close off options – conceding too much control
• Negotiating leverage – competing candidates
38
Commercialisation – Basic Licence Components
• Technology to transfer – protected by IP
• Scope of what’s licensed/transferred
• Type of licence – exclusive/sole/non-exclusive
• Payment – when and how
• Performance – milestones and quality checks
• Manufacturing controls – the China problem
• Enforcement/infringement
39
• Research and development
• Background IP – new IP – who owns what and what happens to it at the end
• Warranties – licensor and licensee
• Product liability
• Term and termination
• Audit – 1 in 10 report accurately
• Boilerplate
Commercialisation – Basic Licence Components
40
• Need a common vision
• Combination of different strengths
– technology
– product delivery
– branding and marketing
• Joint ownership of IP can be difficult
• Control issues
• What happens to the IP on dissolution
Joint Venture Agreements – The Issues
41
Summary & Conclusion
• Honest evaluation of the idea and its potential
• Honest evaluation of the help you need
• One size does not fit all
• Capital providers are sceptical− Capital is expensive
• Distribution is the key
• Licensing / risk sharing is often the way to go BUT:
Be cautious in - Setting royalty rates- Selecting your partners
42
Thank You
Recommended